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A B S T R A C T
Background: The meta-analysis by Furukawa et al. (The Lancet Psychiatry 2019, 6(7)) reported optimal doses
for antidepressants in adult major depressive disorder (MDD). The present reanalysis aimed to adjust optimal
doses in dependence on age. Methods: Analysis was based on the same dataset by Cipriani et al. (The Lancet
2018, 391(10128)) comparing 21 antidepressants in MDD. Random-effects Bayesian network meta-analysis
was implemented to estimate the combined covariate action using restricted cubic splines (RCS). Balanced
treatment recommendations were derived for the outcomes efficacy (response), acceptability (dropouts for
any reason), and tolerability (dropouts due to adverse events). Findings: The combined covariate action of
dose and age suggested agomelatine and escitalopram as the best-balanced antidepressants in terms of effi-
cacy and tolerability that may be escalated until 40 and 60 mg/day fluoxetine equivalents (mg/dayFE), respec-
tively, for ages 3065 years. Desvenlafaxine, duloxetine, fluoxetine, milnacipran, and vortioxetine may be
escalated until 2040 mg/dayFE, whereas bupropion, citalopram, mirtazapine, paroxetine, and venlafaxine
may not be given in doses > 20 mg/dayFE. Amitriptyline, clomipramine, fluvoxamine, levomilnacipran,
reboxetine, sertraline, and trazodone revealed no relevant balanced benefits and may therefore not be rec-
ommended for antidepressant treatment. None of the antidepressants was observed to provide balanced
benefits in patients >70 years because of adverse events exceeding efficacy. Interpretation: Findings suggest
that the combined covariate action of dose and age provides a better basis for judging antidepressant clinical
benefits than considering dose or age separately, and may thus inform decision makers to accurately guide
antidepressant dosing recommendations in MDD. Funding: No funding.








The recent meta-analysis by Furukawa et al. [1] reported optimal
doses for the use of antidepressants in the acute-phase treatment of
adult major depressive disorder (MDD). Results showed a moderate
dose-dependent increase in efficacy (response rate) until 40 mg/day
fluoxetine equivalents (mg/dayFE) associated with an exponential
decrease in tolerability (dropouts due to adverse effects) up to
80 mg/dayFE [2,3]. The current recommendation is therefore that the
lower range (2040 mg/dayFE) of the licensed dose (2080 mg/dayFE)
probably achieves an optimal balance between efficacy and tolerabil-
ity for the majority of patients receiving antidepressants in MDD [1].
The meta-analysis by Furukawa et al. [1] however did not adjust dos-
ing for age, another important demographical covariate in antide-
pressant treatment [410]. Antidepressant use in the elderly ( > 60
years) is associated with an increased risk of potentially clinical sig-
nificant adverse events (AEs). Common AEs affect the cardiovascular
system (e.g., orthostatic hypotension, QTc interval prolongation),
metabolic system (e.g., weight gain, hyponatremia), the central ner-
vous system (extrapyramidal symptoms), and are associated with
osteoporosis, falls and fractures [1113]. The increased risk of AEs
might in part be due to dosing not taking into account known age-
related changes in antidepressant pharmacokinetics and/or drug-
drug interactions (DDIs) [1416]. DDIs are more common in the
elderly due to the prescription of multiple medications under co-
morbid conditions [17]. Indeed, antidepressant prescribing in older
adults has recently been reported to be pharmacokinetically inappro-
priate in 77% (underuse) and 42% (overuse) [18], with a subset of
patients experiencing pharmacodynamic tolerance after long-term
treatment [19]. Antidepressant use is also associated with higher sui-
cidality [20], particularly in elderly men (completed suicides) [21,22]
but also in patients < 25 years (not completed suicides) [23]; with
the latter also having a higher risk of hyperarousal events in response
to antidepressants [24]. Together, age is an important consideration
for whether, when, and how to treat a patient with antidepressants
throughout the life cycle, and with what potential risk versus benefit.
It therefore seems sensible to adjust antidepressant treatment rec-
ommendations for both dose and age to optimally meet the needs ofE-mail address: lisa.holper@bli.uzh.ch
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individual age-groups. The present reanalysis therefore asked
whether antidepressant dosing recommendations reported by Furu-
kawa et al. [1] would change in dependence on age.
The present analysis made use of the same dataset assessed by Fur-
ukawa et al. [1], the GRISELDA dataset provided by Cipriani et al. [25].
which compares 21 antidepressants in adult MDD based on 522 ran-
domized controlled trials (RCTs). Furukawa et al. [1] selected 77 fixed
dose trials and collapsed antidepressants based on their mechanisms
of actions [26] across selective serotonin reuptake inhibitors (SSRIs)
with separate analyses for mirtazapine and venlafaxine. Earlier meta-
analyses also focused on SSRIs [1,27,28] or a limited number of antide-
pressants (citalopram, paroxetine, sertraline) [29]. Clustering analysis
into class-based approaches may increase the evidence base and preci-
sion of effect estimates, but the direct interpretation of individual anti-
depressants is lost, which makes clinical decision making difficult. The
present analysis therefore aimed to evaluate optimal dosing for all 21
individual antidepressants available.
To account for potential nonlinearity of dose phenomena, Furu-
kawa et al. [1] fitted a nonlinear model using restricted cubic splines
(RCS) [30] as implemented in the dosresmeta package [31]. This
approach allows for convenient and robust multivariate dose-
response meta-analysis from aggregated data using flexible non-lin-
ear models. The method is, however, not based on the Bayesian
framework, which is still considered the gold standard for network
meta-analysis (NMA) [32]. The present analysis therefore aimed to
implement a nonlinear model based on RCS into Bayesian NMA. The
implementation further aimed to adjust not only for separate covari-
ates (i.e., dose or age) but also for the combined covariate action. The
methodological approach presented here thus provides the first
example how nonlinear combined covariate effects can be analyzed
and graphically presented based on Bayesian NMA. The results are
expected to support clinical decision making in defining optimal dos-




2.1.1. Bayesian models for NMA
Based on standard Bayesian random-effects NMA [32], a model
based on restricted cubic splines (RCS) was implemented to assess non-
linear treatment-by-covariate interactions with two continuous covari-
ates (xa/xb, i.e., dose and age). The spline basis matrices for the main
covariate effects were generated using the function rcs and those for
the interaction effects, i.e., the tensor product splines, were generated
using the restricted interaction operator %ia%, both implemented in the
rms package [33]. Interaction effects were restricted to be not doubly
nonlinear with products involving nonlinear effects on both covariates
not included in the model. The RCS model was assessed using 3 knots
based on combinations out of 7 possible knot locations for each covari-
ate (dose (mg/dayFE) = [10, 20, 30, 40, 50, 60, 70]; age (years) = [35, 40,
45, 50, 55, 60, 70]), resulting in N = 35 models per covariate. This
allowed for a more extensive selection of the optimal knot location
compared to Furukawa et al. [1], who evaluated only 8 different knot
combinations. The full model contained regression coefficients for the
main covariate effects (B1a,b, B2a,b corresponding to the linear and non-
linear main effect components) and the interaction effects (B3, B4, B5 cor-
responding to the linear and nonlinear interaction effect components).
Covariates were centered and standardized by subtracting the
mean (x) and dividing by the standard deviation (SD, s). Standardi-
zation facilitates the interpretation of beta estimates derived from
covariates with different units for direct comparison of their con-
tribution in determining the outcomes. Missing covariate data
were given informative priors normally distributed xieNðx;s
2Þ
common across trials, an imputation technique assuming covariate
data to be missing at random.
Treatment-by-covariate interactions were assumed to be
exchangeable-related drawn from a random distribution with com-
monmean (B) and between-treatment variance (s2B) [32].
Modeling was conducted using the JAGS software (version 4¢3¢0)
[34]. Simulations were run for 3 chains with an adaptive phase of
100,000, a burn-in of 100,000, and a sampling phase of 200,000 itera-
tions, thinned such that every 50th iteration was retained. Effect sizes
on the log odds ratio (LOR) scale were estimated at 10 equally spaced
covariate values (Fig. S2). Convergence was ensured by considering
the BrooksGelmanRubin diagnostics [35] with the potential scale
reduction factor R  1.05 accepted as implying convergence [36].
Bayesian model selection of the best-fitting RCS model was based on
the deviance information criterion (DIC), a measure of goodness-of-
fit and complexity [36]. The supplementary appendix provides details
on the code used to conduct the analysis.
2.1.2. Balanced treatment recommendations
Since clinical decisions are made not only based on efficacy or tol-
erability separately, but also by considering the best mixture between
outcomes, balanced benefits were assessed for each antidepressant.
For this purpose, the relative treatment effects between two outcomes
were mapped onto the octants of the two-dimensional coordinate sys-
tem (Fig. S6). Balance mapping was defined with the balanced log
odds ratio (LORB) scale representing the balance between the relative
treatment effects of efficacy (x, mapped on the x-axis) versus tolerabil-
ity (y, mapped on the y-axis) compared to placebo (zero). This was cal-
culated as a function of covariate values along the dose (i) and age (j)
dimensions, with LORBði; jÞ ¼ xði; jÞyði; jÞ for mapping on the 1st4th
octant and LORBði; jÞ ¼ xði; jÞ for mapping on the 5th8th octant. Bal-
anced benefits were assumed if the balance on the LORB scale was in
favor of efficacy, i.e., if the balance was mapped onto the 1st, 7th, or
8th octant. In order to avoid balanced treatment recommendations
being driven by implausible interferences based on potential extrapo-
lation in NMA results [37], recommendations were constrained to the
actual dose ranges of individual antidepressants available in the data.
The supplementary appendix provides details on the definition of the
balanced dose recommendations.
2.2. GRISELDA dataset
The GRISELDA dataset [38] provided by Cipriani et al. [25] com-
prises 522 RCTs (total of 116,477 patients) conducted between 1979
and 2016. The dataset compares 21 antidepressants, agomelatine
(AGO), amitriptyline (AMI), bupropion (BUP), citalopram (CIT), clo-
mipramine (CLO), desvenlafaxine (DES), duloxetine (DUL), escitalo-
pram (ESC), fluoxetine (FLO), fluvoxamine (FLV), levomilnacipran
(LEV), milnacipran (MIL), mirtazapine (MIR), nefazodone (NEF), par-
oxetine (PAR), reboxetine (REB), sertraline (SER), trazodone (TRA),
venlafaxine (VEN), vilazodone (VIL), and vortioxetine (VOR),
together forming a network of N = 101 treatment-by-treatment
comparisons (Fig. S1). Information on age (mean 44¢3 § 8¢8, range
3080 years) was available in 451 (86%) trials comprising 105,469
patients. Information on dose (mean 30¢4 § 14¢6, range 580 mg/
dayFE) was available in 497 (95%) trials comprising 110,641 patients
(placebo arms not shown in plot). Doses were converted to 20 mg/
day fluoxetine equivalents (mg/dayFE) using the conversion by Hay-
asaka et al. [2], supplemented by the daily defined dose (DDD)
method [3]. Only vilazodone had no defined equivalent and is there-
fore only reported in the supplementary appendix. The analysis
included 48 (9%) trials with dosages outside the licensed ranges
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approved by the regulatory agencies in the USA and Europe (Table
S1 and Fig. S2).
The primary analysis included 188 fixed dose trials, results of which
are reported in the main text. Nefazodone had no fixed dose trials and
was therefore not included in the primary analysis. The secondary anal-
ysis included 499 trials with both fixed and flexible doses (based on
mean flexible ranges), results of which are reported in the supplemen-
tary appendix. The inclusion of flexible dose trials has been criticized
because of the inevitable confounding between response and dose for
individual patients and hence the likelihood of the aggregated data
being uninformative regarding the actual doses given [39,40].
Primary outcomes were efficacy in terms of response rate (  50%
reduction on the Hamilton Depression Rating Scale, HDRS-17) [41],
acceptability (dropout rate for any reason, dropoutANY), and tolerabil-
ity (dropout rate due to adverse events, dropoutAE). Secondary out-
come was remission rate ( < 7 or < 8 on the HDRS-17 score), results
of which are reported in the Supplementary Appendix.
3. Results
3.1. Bayesian model selection
Best-fitting RCS model were selected based on the smallest DIC
(Table S2). Covariate dose fitted best with knots located at [10, 20, 40]
mg/dayFE; these knots are located at areas with greater covariate density
(Fig. S2) compared to those reported by Furukawa et al. [1] ([10, 20, 50]
mg/dayFE), and may therefore reflect dose phenomena better. Covariate
age was best described with knots located at [40, 45, 60] years; these
knots are reasonable because of the relatively large contribution of
the upper end of the age spectrum to treatment effects (Fig. S3) [37].
3.2. Combined covariate action
The combined covariate action of doseRCS & ageRCS based on the
best-fitting RCS models reduced between-trial heterogeneity (s) by
29% (efficacy), 51% (acceptability), and 59% (tolerability) relative to
the unadjusted model (Fig. S4). Heterogeneity was low for efficacy
(s = 0.026) and acceptability (s = 0.018), and moderate for tolerabil-
ity (s = 0.061) [42]. Maximum effect sizes were medium for efficacy
(LOR 0.61, d = 0.34), acceptability (LOR 0.25, d = 0.14), and tolerability
(LOR 1.02, d = 0.56) compared to Cohen’s d [43]. For brevity, the com-
bined covariate action is illustrated across all antidepressants (Table 1
and Fig. 1), while details on individual antidepressants can be found
in the supplementary appendix (Table. S3 and Fig. S5S7).
Dose adjustment revealed no significant effects on efficacy and
acceptability, but significantly affected tolerability (Table 1). Particu-
larly, main effects of dose suggested a nonsignificant linear increase
in efficacy with increasing dose. Efficacy was best described as weak
linear increasing curves, without decreasing trends as reported by
Furukawa et al. [1] Acceptability (dropoutANY) was unaffected
reflected by flat curves. By contrast, tolerability (dropoutAE) was sug-
gested to strongly linearly decrease with increasing dose in all anti-
depressants (fixed dose trials: linear common B = 0.66, 95% CrI
[0.211.08]; fixed and flexible dose trials: linear common B = 0.61,
95% CrI [0.191.03]). Tolerability was best described by steep linear-
plateau curves, which settled approximately at 20 mg/dayFE after
which curves increased flatter until 80 mg/dayFE, compared to the
more exponential curve reported by Furukawa et al. [1] Estimates of
the decrease in tolerability were found to be more than double the
size of the increase in efficacy, in line with Furukawa et al. [1].
Age adjustment revealed no significant effects on efficacy, but
affected both acceptability and tolerability (Table 1). In particular,
main effects of age suggested a nonsignificant nonlinearly decrease
in response with increasing age. Acceptability (dropoutANY) signifi-
cantly decreased with increasing age (fixed dose trials: nonlinear
common B = 0.18, 95% CrI [0.050.42]; fixed and flexible dose trials:
nonlinear common B = 0.21, 95% CrI [0.020.40]). Likewise
dose-adjustment, the strongest effect was observed on tolerability
(dropoutAE) which nonlinearly decreased with from approximately
> 60 years upwards in most antidepressants (fixed dose trials: non-
linear common B = 0.53, 95% CrI [0.101.14]; fixed and flexible dose
trials: nonlinear common B = 0.40, 95% CrI [0.120.69]).
The dominant effects on tolerability (dropoutAE) were supported by a
significant interaction effect between the linear doseRCS £ nonlinear
ageRCS components (fixed dose trials: common B = 1.43, 95% CrI
[3.080.26]; fixed and flexible dose trials: common B = 0.34, 95% CrI
[0.900.23]), suggesting increasing dropouts due to adverse events
with increasing dose and increasing age (Table 1). The remaining
Table 1
Adjusted beta estimates. Standardized common beta estimates (B) adjusted for the combined covariate action of doseRCS & ageRCS and their interaction based on the
best-fitting RCS models in fixed dose trials. Listed are the linear and nonlinear main effect components of doseRCS and ageRCS (B1a,b, B2a,b), and the linear and nonlin-
ear interaction effect components between doseRCS £ ageRCS (B3, B4, B5). Statistical significant betas (95% CrI excluding zero) are highlighted (*). See Table S3 for
details on individual antidepressants.
Fixed dose Fixed and flexible dose
Dose B1a (95% CrI) B2a (95% CrI) B1b (95% CrI) B2b (95% CrI)
Linear Nonlinear Linear Nonlinear
Response 0.11 (0.180.44) 0.03 (0.430.34) 0.09 (0.110.30) 0.01 (0.260.24)
Remission 0.19 (0.120.51) 0.07 (0.480.33) 0.13 (0.110.36) 0.06 (0.340.24)
DropoutANY 0.29 (0.040.67) 0.27 (0.730.14) 0.24 (0.040.48) 0.24 (0.520.06)
DropoutAE 0.66 (0.211.08)* 0.48 (0.99-0.09) 0.61 (0.191.03)* 0.44 (0.930.05)
Age B1a (95% CrI) B2a (95% CrI) B1b (95% CrI) B2b (95% CrI)
Linear Nonlinear Linear Nonlinear
Response 0.03 (0.080.14) 0.11 (0.410.18) 0.02 (0.080.13) 0.12 (0.290.05)
Remission 0.04 (0.070.16) 0.16 (0.430.06) 0.01 (0.120.09) 0.16 (0.340.02)
DropoutANY 0.09 (0.190.01) 0.18 (0.050.42) 0.08 (-0.200.03) 0.21 (0.020.40)*
DropoutAE 0.09 (0.320.14) 0.53 (0.101.14)* 0.09 (0.270.09) 0.40 (0.120.69)*
Dose £ Age B3 (95% CrI) B4 (95% CrI) B5 (95% CrI) B3 (95% CrI) B4 (95% CrI) B5 (95% CrI)
Dose linear £ Dose nonlinear £ Dose linear £ Dose linear £ Dose nonlinear £ Dose linear £
Age linear Age linear Age nonlinear Age linear Age linear Age nonlinear
Response 0.12 (0.290.55) 0.19 (0.700.31) 0.06 (0.600.41) 0.02 (0.280.26) 0.07 (0.250.38) 0.03 (0.290.24)
Remission 0.05 (0.260.34) 0.05 (0.370.45) 0.09 (0.380.20) 0.20 (0.500.08) 0.27 (0.050.61) 0.12 (0.180.41)
DropoutANY 0.04 (0.440.42) 0.09 (0.480.63) 0.02 (0.290.24) 0.07 (0.590.36) 0.03 (0.450.59) 0.04 (0.370.52)
DropoutAE 0.43 (0.060.92) 0.45 (1.040.15) 1.43 (3.080.26)* 0.37 (0.290.96) 0.44 (1.090.27) 0.34 (0.900.23)
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interaction effects were not significant suggesting that dose and age act
as independent moderators on response, remission, and dropoutANY.
3.3. Balanced treatment recommendations
Balanced benefits based on the combined covariate action were
assessed for individual antidepressants. The balance between efficacy
(response) and tolerability (dropoutAE) is explained in Fig. 2 and illus-
trated Figs. 3 and 4 (Table 2), while details on other outcomes can be
found in the supplementary appendix (Fig. S6).
 Best-balanced antidepressants were suggested to be agomelatine
and escitalopram because of their favorable relation between effi-
cacy and tolerability. Pooled effect estimates of agomelatine were
found to be mapped on the 1st octant indicating adverse events
being overall smaller in effect size than those of efficacy, whereas
pooled effect estimates of escitalopram were mapped on the bor-
der between the 1st and 8th octant indicating effects of efficacy
and tolerability being overall equal in size (Fig. 3). Both antide-
pressants were suggested for ages 3065 years, which is a larger
age range compared to most of the other drugs (Fig. 4).
 Agomelatine was suggested to allow for dose escalation up to
40 mg/dayFE, corresponding to approximately 50 mg/day agome-
latine, which is the upper end of the licensed dose range
2550 mg/day (Table 2 and Fig. 4). This dose recommendation
has been constrained to 40 mg/dayFE because the actual dose
range for agomelatine investigated in the trials was limited to
38 mg/dayFE; any higher doses suggested by the NMA results
might be affected by extrapolation [37], most likely due to the
direct and indirect evidence coming from comparisons with esci-
talopram, fluoxetine, or venlafaxine Fig. S3, which were dosed
> 40 mg/dayFE (Table 2).
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Fig. 1. Covariate adjusted meta-regression plots. Antidepressant effects relative to placebo illustrated for the main effects of (Top) doseRCS, (Middle) ageRCS, and (Bottom) the combined
covariate action of doseRCS & ageRCS in fixed dose trials. Values greater 0 on the log odds ratio (LOR) scale indicate increase in response/remission or increase in dropoutANY/AE com-
pared to placebo. Plots illustrate the averaged effect sizes across all antidepressants; see Fig. S5 for individual antidepressants.
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 Escitalopram was suggested to allow for dose escalation up to
60 mg/dayFE (Fig. 4), also constrained to the actual dose range
available in the data. This dose is slightly above the correspond-
ing licensed dose range (60 mg/dayFE corresponds to approxi-
mately 27 mg/day escitalopram, licensed dose range 1020 mg/
day, Table 2), and should therefore only be considered if clinically
justified. ny higher doses suggested by the NMA results might be
affected by extrapolation,[37] most likely due to direct and indi-
rect evidence coming from comparisons with sertraline or venla-
faxine Fig. S3, which were dosed up to 80 mg/dayFE (Table 2).
 Balanced benefits for most of the other antidepressants were
found to be mapped on the 2nd octant indicating an overall
imbalance to the disadvantage of efficacy (Fig. 3). Desvenlafaxine,
duloxetine, fluoxetine, milnacipran, and vortioxetine were sug-
gested to be escalated until 2040 mg/dayFE, whereas bupropion,
citalopram, mirtazapine, paroxetine, and venlafaxine may not be
given in doses > 20 mg/dayFE (Fig. 4).
 The remaining antidepressants amitriptyline, clomipramine, flu-
voxamine, levomilnacipran, reboxetine, sertraline, and trazodone
revealed no relevant balanced benefits because of adverse events
exceeding efficacy, as mapped on the 2nd or even 3rd octant
indicating an imbalance due to low efficacy and/or low tolerabil-
ity (Figs. 3 and 4). These antidepressants may therefore not be
recommended for treatment.
 All antidepressants may require dose reductions in patients
> 65 years, in order to account for the nonlinearity in age effects
on tolerability.
Discussion
The present analysis demonstrates that the combined covariate
action of dose and age is of clinical relevance for balanced antidepres-




























































Fig. 2. Color scheme defining balanced mapping. Two-dimensional graph illustrating the color scheme used to define the balance mapping between efficacy (response) versus tolera-
bility (dropoutAE) on the balanced log odds ratio (LORB) scale. Blue colors indicate a balance in favor of efficacy, and vice versa, red color indicate a balance in favor of dropouts.
Octants quantifying the balance between efficacy and tolerability are numbered.
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reported by Furukawa et al. [1] and other earlier dose-response meta-
analyses [2729], in that they demonstrate that dosing recommenda-
tions may not be generalized across antidepressants but may be
considered drug-specific with age as a potential limiting moderator.
Agomelatine and escitalopram were suggested as favorable bal-
anced antidepressants which may be explained based on their phar-
macological profiles. Agomelatine, combining norepinephrine and
dopamine disinhibition (NDDI) plus melatonergic agonism [44], has a
favorable adverse effect profile mostly due to the fact that it does not
affect sexual functioning, weight gain, or metabolic syndrome, and
positively regulates sleep quality [45,46]. The balance benefit
observed in the present analysis for agomelatine is thus due to its rel-
atively good tolerability and not due to superior efficacy. This is in
line with Cipriani et al. [25], who ranked agomelatine as the best
acceptable (1st rank) but only moderate efficacious (12th rank) anti-
depressant (Fig. S7). Its comparable low efficacy may be a reason why
agomelatine is still one of the less frequently used antidepressants
[47]. The present analysis suggests potential dose escalation until
40 mg/dayFE, which is the upper limit of its licensed range (Table 2).
Escitalopram, after citalopram one of the most commonly used
antidepressants [47], has a unique mechanism among SSRIs. While
the exact mechanism is unclear, the most common explanation why
escitalopram seems to be more effective than citalopram, is that there
is a synaptic interaction for the racemat citalopram (which consists of
the S- and R-citalopram enantiomers), in that the presence of R-cita-
lopram somehow inhibits the more active S-citalopram in the bind-
ing to the serotonin (5-hydroxytryptamine [5-HT]) site of the
serotonin transporter (SERT) [48,49]. Therefore, escitalopram (con-
sisting only of the S-citalopram enantiomer) has a pharmacologically
greater therapeutic range and a more rapid mode of action. This
raises the possibility of increasing efficacy with increasing dose,
which has previously been suggested as useful strategy in MDD [50].
Unlike agomelatine, the favorable balance observed here for escitalo-






































































Fig. 3. Balanced treatment recommendations: average across covariate values. Two-dimensional graph illustrating the balance between efficacy (response) versus tolerability (dro-
poutAE) based on the combined covariate action of doseRCS & ageRCS in foxed dose trials. Blue colors indicate a balance in favor of efficacy, and vice versa, red color indicate a balance
in favor of dropouts on the balanced log odds ratio (LORB) scale. Individual drugs are indicated by nodes representing the median across covariate values along the dose and age
dimensions. Size of the nodes represent the relative treatment effects weighted by the inverse variance method [55] (i.e., one divided by the standard error squared), such that treat-
ment effects with greater precision (smaller CrIs) are represented by larger points than those with smaller precision (wider CrIs), a method to minimize the imprecision of pooled
effect estimates. Octants quantifying the relationship between efficacy and tolerability are numbered. See Fig. S6 for details on all trials.
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tolerability (3rd rank), as ranked by Cipriani et al. [25] (Fig. S7). The
present analysis suggests potential dose escalation until 60 mg/dayFE,
which is slightly above the upper limit of its licensed range (Table 2).
The remaining antidepressants were found to have balanced bene-
fits within smaller dose ranges. Balanced treatment recommendations
suggest that some antidepressants may be given until 2040 mg/dayFE
(desvenlafaxine, duloxetine, fluoxetine, milnacipran, and vortioxetine),
whereas others may not be used > 20 mg/dayFE (bupropion, citalo-
pram, mirtazapine, paroxetine, and venlafaxine). A considerable num-
ber of antidepressants (amitriptyline, clomipramine, fluvoxamine,
levomilnacipran, reboxetine, sertraline, and trazodone) revealed no
balanced benefits at all and may therefore not be recommended for
antidepressant treatment because of their questionable clinical benefit.
Limiting the present analysis is the fact that information available
on the low dose range (540 mg/dayFE, 82%) was substantially larger
than on the high dose range (4080 mg/dayFE, 18%) (Fig. S2). Inter-
pretation should therefore consider that effects presented for high
dosages may be less reliable due to intra- and extrapolation of covari-
ate information taking place (Fig. S3) [37]. Interpretation should also













































































Fig. 4. Balanced treatment recommendations: as a function of covariate values. Heatmaps representing balanced benefits between efficacy (response) and tolerability (dropoutAE)
based on the combined covariate action of doseRCS & ageRCS in fixed dose trials. Colors code the balance between efficacy and tolerability on the balanced log odds ratio (LORB) scale,
with blue colors indicating a balance in favor of efficacy, and vice versa, red colors indicating the balance in favor of dropouts. The corresponding color scheme mapping the balance
on the octants of the two-dimensional coordinate system can be found in Fig. 2. See Fig. S6 for details on all trials.
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in the present analysis to derive dosage equivalents [2,3] may pro-
duce different effects.
Age was suggested as potential limiting moderator for antidepres-
sant dosing recommendations. While doses reported here may be tol-
erable in patients between 3065 years of age, patients > 65 years
may require dose reductions. Indeed, none of the antidepressants was
observed to provide balanced benefits in patients > 70 years because
of adverse events exceeding efficacy. Again, limiting the present
results is the fact that information available on ages > 65 years (79%)
was greater than that on > 65 years (21%), as well as that no trials
included patients > 30 years (Fig. S2), which ultimately limits the clin-
ical interferences to be made on both ends of the age spectrum. The
nonlinearity of the observed age effects however supports earlier
reports that the risk-benefit ratio is most favorable for adults between
25 and 65 years, while both younger adults > 25 years, due to an
increased risk of suicidality [23] and hyperarousal events [24], as well
as elderly patients > 65 years, due to more side effects [1116], phar-
macodynamic tolerance [19], and suicidality [2022], may not
respond as well to antidepressants. Considering the presented bal-
anced dosing recommendations may thus not necessarily lead to bet-
ter response rates, but may keep tolerability at endurable levels, which
is important for treatment compliance and adherence.
It should be emphasized that the presented balanced treatment
recommendations are based on statistical significance and not clinical
significance. Criteria for clinical significance in antidepressant treat-
ment have earlier been suggested by the National Institute for Health
and Clinical Excellence (NICE) (Cohen’s d > 0.5) [52], but have later
been criticized for being arbitrary and should therefore be inter-
preted with caution [53]. A measure of clinical significance for antide-
pressant treatment however would be helpful to judge wether the
presented balanced recommendations are transferable to antidepres-
sants’ real-world benefits.
It should also be considered that other covariates, such as depres-
sion severity or gender, as well as plausible risk of bias not accounted
for by the covariates may also affect treatment recommendations,
with the latter being primarily due to study limitations, imprecision,
and publication bias, as revealed by an earlier sensitivity analysis on
the same dataset [54].
In conclusion, the present analysis based on Bayesian NMA may
be viewed as a next step towards optimizing dosage recommenda-
tions for antidepressant treatment in dependence on age. The results
may inform researchers and guideline developers to reconsider the
nonlinearity of dose-age dependencies before generalizing antide-
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Results obtained from the analysis are shared in the supplemen-
tary appendix.
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